- Home
- USIO vs ICCC Comparison
USIO vs ICCC Comparison
Compare USIO & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- ICCC
- Stock Information
- Founded
- USIO 1998
- ICCC 1982
- Country
- USIO United States
- ICCC United States
- Employees
- USIO N/A
- ICCC N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- ICCC Health Care
- Exchange
- USIO Nasdaq
- ICCC Nasdaq
- Market Cap
- USIO 50.2M
- ICCC 60.1M
- IPO Year
- USIO N/A
- ICCC 1987
- Fundamental
- Price
- USIO $1.46
- ICCC $6.56
- Analyst Decision
- USIO Strong Buy
- ICCC
- Analyst Count
- USIO 1
- ICCC 0
- Target Price
- USIO $4.00
- ICCC N/A
- AVG Volume (30 Days)
- USIO 88.1K
- ICCC 7.5K
- Earning Date
- USIO 11-05-2025
- ICCC 08-14-2025
- Dividend Yield
- USIO N/A
- ICCC N/A
- EPS Growth
- USIO N/A
- ICCC N/A
- EPS
- USIO 0.11
- ICCC 0.20
- Revenue
- USIO $83,851,606.00
- ICCC $28,274,756.00
- Revenue This Year
- USIO $8.66
- ICCC N/A
- Revenue Next Year
- USIO $13.32
- ICCC N/A
- P/E Ratio
- USIO $13.42
- ICCC $31.55
- Revenue Growth
- USIO 2.05
- ICCC 21.75
- 52 Week Low
- USIO $1.24
- ICCC $3.34
- 52 Week High
- USIO $2.92
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- USIO 44.97
- ICCC 55.18
- Support Level
- USIO $1.43
- ICCC $6.29
- Resistance Level
- USIO $1.55
- ICCC $6.80
- Average True Range (ATR)
- USIO 0.07
- ICCC 0.20
- MACD
- USIO -0.00
- ICCC 0.05
- Stochastic Oscillator
- USIO 44.44
- ICCC 59.55
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.